Spyre Therapeutics

Forecast & Rating18 analysts currently cover Spyre Therapeutics, with about 88.9% giving a positive rating — meaning they expect the stock to rise. The average price target is $119.71, about 34.5% upside from the current price of $88.98. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 26.6% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Spyre Therapeutics closely still see room for the stock to rise. Data as of Sep 3, 2026; for reference only and not investment advice.